Explanation
This patient belongs in one of the four statin benefit groups because his estimated 10-year ASCVD risk is over
7.5%. Adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, with an estimated 10-year ASCVD risk
7.5% and without clinical ASCVD or diabetes should receive either a moderate-intensity or high-intensity statin. Since the extent of reducing the risk of ASCVD is proportionally related to the degree of LDL-C reduction, risk could be reduced more so with a high intensity statin. Considering the given options, Atorvastatin 80 mg PO QHS is the best choice.